Optiver Holding B.V. Takes $757,000 Position in Genmab A/S (NASDAQ:GMAB)

Optiver Holding B.V. purchased a new position in Genmab A/S (NASDAQ:GMAB) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 36,260 shares of the company’s stock, valued at approximately $757,000.

Other large investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its stake in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after buying an additional 939 shares during the period. Lindbrook Capital LLC boosted its holdings in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares during the period. Barclays PLC lifted its holdings in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after buying an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC lifted its holdings in Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after buying an additional 2,496 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on GMAB shares. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price target (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Sanford C. Bernstein lowered shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday, April 1st. Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, Truist Financial dropped their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $39.17.

Genmab A/S Price Performance

GMAB opened at $20.63 on Tuesday. The company’s 50 day simple moving average is $20.45 and its two-hundred day simple moving average is $21.00. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.41. The firm has a market capitalization of $13.66 billion, a price-to-earnings ratio of 11.86, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.